ADMA Biologics Inc vs Old Dominion Freight Line Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Old Dominion Freight Line Inc trades at $209.64 (market cap $44.07B). The key difference: Old Dominion Freight Line Inc is far larger — about 20.2× ADMA Biologics Inc's market cap, and Old Dominion Freight Line Inc pays a 0.55% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ODFL | |
|---|---|---|
Market Cap | $2.18B | $44.07B |
Sector | Health | Industrials |
52-Week High | $20.38 | $248.73 |
52-Week Low | $7.60 | $126.29 |
Enterprise Value | $2.25B | $43.81B |
Dividend Yield | — | 0.55% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
ODFL stock trades at $216.36, up 2.34% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $1.68 versus $1.54 expected, driven by yield improvements and cost discipline. The company maintains robust profitability with a net income margin of 19.44% and ROE of 24.82%, though revenue has declined from $6.3B in 2022 to $5.5B in 2025. Analyst consensus price target is $239.85, suggesting upside potential.
Outlook is mixed: earnings momentum and a solid balance sheet support growth, but high valuation ratios (P/E of 41.6) and freight volume pressures pose risks. Investors should weigh the premium pricing against operational efficiency gains and market recovery prospects.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →